Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Nonetheless, state rules can impose some extra limitations depending on the purpose of use
All Patriot Labs products are sold for in-vitro research and laboratory use only
Research Interest in IGF-1 LR3 IGF-1 LR3 is frequently discussed in peptide laboratory research because of its structural relationship to Insulin-Like Growth Factor-1 and its modified Long R3 sequence
Goal: Type 2 diabetes management (A1C reduction) If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan) If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin) If you prefer oral medication: Semaglutide (Rybelsus) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions) Goal: Weight loss (obesity or overweight with comorbidities) If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss) If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data) If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide Goal: Both diabetes and weight loss If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication
Grere, verblindete, kontrollierte Studien knnten zeigen, ob die prklinischen Hoffnungen in der Praxis erfllt werden
US$ 24.45
US$ 24.93
US$ 29.42
US$ 22.78
US$ 27.05
US$ 25.83
US$ 29.80
US$ 26.99
US$ 23.25
US$ 29.05
